MAPT and Alzheimer disease: Fluid biomarkers that are routinely studied for AD include amyloid peptides (Aβ40, Aβ42, and their ratio), total tau (t-Tau), phosphorylated tau (pTau), and NfL, measured in both CSF and plasma.